Emcure Pharmaceuticals and Roche have signed a distribution agreement for selected products in nephrology and transplant care. Starting April 1, 2026, Emcure will distribute Roche’s brands within the ...
Emcure Pharmaceuticals has signed a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio. The agreement marks a significant step toward expanding ...
Emcure Pharmaceuticals has inked a distribution pact with Roche for select products in the nephrology and transplant medicine portfolio, effective April 1. The agreement would help expand access to ...
The Business Research Company's Mircera Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...
Please provide your email address to receive an email when new articles are posted on . Even with algorithms available, dosing for Mircera appears to vary widely among nephrologists. Dialysis clinics ...
When it comes to product development, the management of third-party intellectual property (IP) to ensure freedom to operate is of paramount importance. Drug development is no different. Imagine ...
This market research study on Mircera (methoxy polyethylene glycol-epoetin beta) Market offers a thorough assessment and improvement of important producers, rivals, international suppliers, and risks.
Genexine has laid down a marker in its bid to challenge for the chronic kidney disease (CKD)-induced anemia field, showing that its investigational drug candidate matched Roche and CSL Vifor’s Mircera ...
SEOUL, South Korea--(BUSINESS WIRE)--A clinical-staged proprietary platform technology biotech company Genexine (KQ 095700, CEO Neil Warma) and its Asian regional partner, KG Bio unveiled the interim ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results